News

FDA approval has been granted approval to belumosudil for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy.

The combination of the ant-PD-1 inhibitor, pembrolizumab plus chemotherapy before surgery continued by pembrolizumab as a single agent led to statistically significant event-free survival result versus neoadjuvant chemotherapy alone in patients with high-risk early-stage triple-negative breast cancer.

For people living with the one-two punch of both HIV and cancer, coordinated care by a multidisciplinary team that can bring extra resources to bear during treatment offers the best chance of a successful outcome.

The investigational anti-TIGIT agent, COM902, has been administered to a patient for the first time as part of a phase 1 clinical trial evaluating COM902 in combination with the anti-PVRIG agent, COM701 in patients with advanced malignancies who have no alternative treatment options.

In an interview with Targeted Oncology, Stephanie Lee, MD, MPH, reviewed the updated data from the REACH3 trial along with the efficacy of ruxolitinib in the greater chronic graft versus host disease population.

The FDA has lifted its partial clinical hold on a phase 1B study of RVU120, which is an investigation of the agent for the treatment of patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.

In season 2, episode 6 of Targeted Talks, Dr. Michael J. Overman, joins Targeted Oncology for a special discussion around rare genomic alterations in colorectal cancer

A study has shown that Ga-68 PSMA PET imaging predicted lymph node invasion in patients with prostate cancer at a higher specificity and higher positive predictive value compared with 3 nomograms at predicting lymph node invasion.

Gilles Salles, MD, the lymphoma service chief at Memorial Sloan Kettering Cancer Center discusses the safety profile of tafasitamab combined with lenalidomide for the treatment of relapsed or refractory diffuse large B-cell lymphoma, based on results of the L-MIND trial.

In a draft guidance for clinical investigators and sponsors, the FDA made recommendations on how to expand eligibility to patients with incurable cancer through clinical trial designs of investigational cancer drugs and biological products.

The American Society of Clinical Oncology and the Community Oncology Alliance released new Oncology Medical Home standards that are designed to help guide care providers as they treat patients.

In an interview with Targeted Oncology, Rachel N. Grisham, MD, discussed binimetinib’s effect on patients with ovarian cancer harboring a KRAS mutation. 

Encouraging findings from an ongoing phase 1 trial evaluating an off-the-shelf, allogeneic CD30-CAR Epstein Barr virus–specific T-cell therapy, evaluated in patients with lymphoma.

A significant increase in the risk of disease recurrence among patients with high level of the nicotine metabolite, urinary cotinine, who had non–muscle invasive bladder cancer and were smokers.

In an interview with Targeted Oncology, Rachel Wuerstein, MD, discussed the implications of the KAMILLA trial and the benefit of T-DM1. Wuerstein also discussed the data that show TDM1’s potential use for patients with HER2-positive metastatic breast cancer beyond the standard-of-care second-line setting.

Chevon Rariy, MD, discusses how the coronavirus disease 2019 pandemic has impacted the adoption of telehealth and the creation of the in-home infusion program, which allows cancer patients to continue their treatment at home while quarantining.

The first patient with a solid tumor has been dosed in the TiTAN-1 clinical trial, which is aiming to determine the safety, tolerability, and efficacy of GEN-011, a next-generation neoantigen adoptive cell therapy.

Eleni Gkika, MD, a radiation oncologist at the University Medical Center Freiburg, discusses the future of treatment for patients with advanced hepatocellular carcinoma.

Neoadjuvant osimertinib is effective and feasible for use as treatment for patients with stage II-IIIB EGFR-mutant lung adenocarcinoma, according to interim analysis results of the NEOS study.

Sequencing of over 5,000 cases of patients with metastatic castration resistant prostate cancer showed potential for identifying multiple biomarkers in MSH6-mutated cases.

In an interview with Targeted Oncology, David W. Dougherty, MD, discussed how the COVID-19 pandemic has changed the cancer care space.

In an interview with Targeted Oncology, Peter Martin, MD, discussed the real-world findings and how future agents should be developed to ensure optimal benefit for all patients with mantle cell lymphoma.

The FDA has granted approval to the combination of daratumumab and hyaluronidase-fihj and pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior line of therapy, including lenalidomide and a proteasome inhibitor.

The FDA has granted approval to enfortumab vedotin for the treatment of adult patients with locally advanced or metastatic urothelial cancer.

David M. O’Malley, MD, discusses the prognosis and historical treatment options for patients with platinum-agnostic ovarian cancer.

In an interview with Targeted Oncology, Eugene Ahn, MD, reviewed the data from the uterine cancer cohort of the TAPUR study and explained the implications of the findings.

ARO-HIF2, an investigational tumor-targeting medicine utilizing the Targeted RNAi molecule platform from Arrowhead Pharmaceuticals, Inc., may be a safe and effective treatment for patients with clear cell renal cell carcinoma.

The FDA has placed a partial clinical hold on clinical trials evaluating the first-in-class peptide-drug conjugate, melphalan flufenamide pending a full benefit/risk profile on the agent for use as an early line of therapy in patients with relapsed or refractory multiple myeloma.

In an interview with Targeted Oncology, Toni K. Choueiri, MD, discussed the results of the KEYNOTE-564 trial as well as the potential effects of these findings.

In an interview with Targeted Oncology, Eugene Ahn, MD, discussed the new care delivery model being tested at the Cancer Treatment Centers of America and how it can help patients with cancer in underserved communities.